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Salvage therapy with high-dose chemotherapy (HDCT) and bone marrow transplant (BMT) or peripheral
blood stem cell transplant (PBSCT) has curative potential in patients with recurrent germ cell tumor. However,
patients with primary mediastinal nonseminomatous germ cell tumors (PMNSGCTs) have had poor results
with any form of salvage chemotherapy including HDCT. We switched from BMT to PBSCT in 1996. One
hundred sixteen of 184 patients (63%) with recurrent or refractory germ cell tumors treated from 1996 to
2004 were alive and continuously disease-free. PMNSGCTs were excluded from that study because of poor
results in the patient population with HDCT and BMTs. In 2006, we resumed treating patients with recurrent
PMNSGCT with 2 consecutive courses of HDCT consisting of carboplatin 700 mg/m2  3 plus etoposide 750
mg/m2  3 and each followed by an infusion of autologous peripheral-blood hematopoietic stem cells with
a second course 3 to 4 weeks later. Twelve patients were treated: 11 as initial salvage chemotherapy and 1 as
fourth-line therapy. Eight of the 12 patients had major thoracic resections at the time of the relapse after
initial chemotherapy. Three of the 12 patients achieved complete remission (CR; 10, 15, and 50 months’
duration). One patient remains continuously with no evidence of disease (NED) at 50 months. An additional
patient is currently NED at 52 months with HDCT and subsequent surgery. Median survival for the 12 patients
was 11 months (range, 4-52 months). Results with tandem transplant for recurrent PMNSGCT remain poor
compared to primary testis cancer, but durable CR and probable cure can be achieved in a small subset of
patients with PMNSGCT. In our opinion, salvage surgical resection if anatomically feasible is the preferred
option for patients with PMNSGT progressing after initial chemotherapy.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Germinal epithelium forms in the yolk sac during the
embryologic development, undergoes midline migration
from the dorsal mesentery of the hindgut to the urogenital
ridge, and ﬁnally forms the testes in the scrotal sac. Primary
mediastinal germ cell tumors arise because cells can remain
in the anterior mediastinum and become malignant despite
normal testes bilaterally.
Primary mediastinal germ cell tumors account for 15% of
adult anterior mediastinal tumors and 1% to 5% of all germ
cell malignancies [1,2]. They are histologically and serologi-
cally identical to their testicular counterparts, but they have
markedly different biologic and clinical outcomes [3,4].
Patients with testicular cancer are curable even with
advanced metastatic disease or recurrence after initial
chemotherapy [5].
Primary mediastinal nonseminomatous germ cell tumors
(PMNSGCTs) are always characterized as poor-risk diseasedgments on page 163.
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markers of human chorionic gonadotropin (hCG) and alpha
fetoprotein (AFP) [6]. Patients who relapse after initial
cisplatin-based chemotherapy have an extremely dismal
outcome with an overall survival of 10% [4]. These are
distinctly inferior results with salvage chemotherapy
compared to patients with testicular cancer or primary
mediastinal seminoma. A cure rate of 70% can be achieved
with high-dose chemotherapy (HDCT) and peripheral stem
cell transplant (PBSCT) when used as initial salvage chemo-
therapy [7].
We have previously published our results with HDCT for
relapsed PMNSGCTs [8,9]. Twelve patients with PMNSGCTs
received HDCT with autologous bone marrow transplant
(BMT) from 1988 to 1996. All 12 patients relapsed within 1
year of HDCT. Only 5 of these 12 patients received the planned
2 courses of HDCT. The remainder had only 1 round of
chemotherapy either because of inadequate response
(3 patients) or excessive toxicity (4 patients). Two patients
died during the peritransplantation period due to sepsis and
due to thrombocytopenic bleeding. The median survival was
only 6 months. No patient achieved a complete remission
(CR). Similar poor results were also observed from other
centers worldwide [2]. We, therefore, abandoned the use of
salvage HDCT with bone marrow because of the poor results.
Hematopoietic stem cell rescue shifted from BMT to PBSCT at
our center in 1996, which allowed for rapid engraftmentwith
Table 1
Baseline Characteristics of 12 Patients with PMNSGCTwho underwent HDCT






















Time to relapse from ﬁrst chemotherapy
Median 0 months
Range 0-7 months
Salvage surgery (before HDCT) 8 (67%)
Resection of mediastinal mass 8
Resection of lung mass 3
Platinum refractory 7 (58%)
PMNSGCT indicates primary mediastinal nonseminomatous germ cell
tumor; HDCT, high-dose chemotherapy; AFP, alpha fetoprotein; hCG,
human chorionic gonadotropin.
Table 2








Surgery after transplantation 3 (25%)
Viable tumor 3/3
Palliative radiation after transplantation 4 (33%)
Subsequent therapy
Gemcitabine and paclitaxel 6
Sunitinib 2
Gemcitabine and oxaliplatin 1
Bevacizumab and oxaliplatin 1
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etoposide 3 to 4weeks after the ﬁrst course as opposed to 4 to
6 weeks with BMT. We published our results with high-dose
salvage chemotherapy followed by PBSCT in 184 consecutive
patients with relapsed germ cell tumors. Patients with
PMNSCTswere excluded. Onehundred sixteenof 184patients
(63%) achieved a 2-year continuous disease-free survival
(DFS) [7]. These results represented improvement from our
earlier studies with HDCT and BMT. This improvement,
compared to our historical controls, could be attributed to
better patient populations, improved supportive care, or the
ability to administer the second course of HDCT in 3 to 4
weeks rather than 4 to 6 weeks with BMT.
Therefore, in 2006, we resumed HDCT and PBSCT in
patients with recurrent PMNSGCTs, with the hope and
expectation that we would have improved survival, CRs, and
potential for cure.
PATIENTS AND METHODS
Between 2006 and 2008, 12 patients with a diagnosis of PMNSGCT were
treated with salvage HDCT and PBSCT. PMNSGCTs were deﬁned as a non-
seminomatous germ cell tumor arising in the mediastinum without
demonstrable testicular abnormalities, as determined by physical exami-
nations and/or testicular ultrasonography. All 12 patients had progressed
after standard cisplatin combination therapy. Peripheral-blood stem cells
were collected and puriﬁed according to a technique that has been
described previously [10]. We harvested the cells after stimulation of the
patient’s marrow with granulocyte colony-stimulating factor and enriched
these cells for CD34þ hematopoietic cells. The patients were treated with 2
consecutive courses of HDCT consisting of carboplatin 700 mg per square
meter plus etoposide 750 mg per square meter, each for 3 consecutive days.
Both carboplatin and etoposide were given i.v. 5, 4, and 3 days before the
infusion of peripheral-blood stem cells. A minimum of 1million CD34þ cells
per kilogram of body weight was required for each cycle of HDCT. Antibi-
otics, including prophylactic acyclovir, ﬂuconazole, ciproﬂoxacin, and van-
comycin were used routinely [7].
The second cycle of HDCT was given 3 to 4 weeks after initiation of the
ﬁrst course, unless there was no response to the ﬁrst course ofchemotherapy. Patients who had CR or partial remission with normal hCG
and AFP after the 2 cycles of HDCT received a maintenance oral dose of 50
mg of etoposide per square meter daily for 21 consecutive days every 4
weeks for 3 cycles as previously described [7,11]. CR was deﬁned as no
clinically or radiographically detectable disease and normal serum levels of
hCG and AFP. Patients with a resectable residual mass after HDCT were
offered surgery. DFS, deﬁned as no evidence of disease at all follow-up visits
after HDCT, was the primary endpoint for this analysis. Survival time was
measured from the ﬁrst day of HDCT. DFS was measured from the initiation
of HDCT to tumor progression or death.
RESULTS
Twelve patients were treated with tandem HDCT and
PBSCT: 11 as initial salvage chemotherapy and 1 as fourth-
line therapy. Patients’ characteristics including serum tumor
markers, site of metastasis, platinum refractoriness to ﬁrst-
line chemotherapy, and histology are detailed in Table 1.
Eight patients had major thoracic resections before HDCT.
The median time from ﬁrst relapse to institution of PBSCT
was 7.5 months (range, 4-20 months). Three of the 12
patients (25%) achieved CR with HDCT (10, 15, and 50
months). One of 3 patients relapsed and died 6 months after
achieving CR, whereas the other 2 patients are still alive. The
second patient presented with an 11-cm right lower lobe,
a 4.7-cm retrosternal, and a 2-cm left upper lobe mass.
Histology was a yolk sac tumor with AFP 34756 ng/mL. Initial
chemotherapy was givenwith AFP nadir of 76 ng/mL but rose
within 4 weeks. Imaging studies showed persistent medi-
astinal mass with inﬁltration of the sternum. Salvage surgery
revealed 95% necrosis and 5% yolk sac tumor in both the
sternum and the anterior mediastinum mass. He relapsed
with elevated AFP 110 ng/mL 4 months later. He was treated
with HDCT and followed by 3 months of maintenance daily
oral etoposide. He relapsed 15 months after attaining a CR.
Imaging studies revealed a solitary lesion in the upper left
lobe of the lung with AFP 326 ng/mL. Subsequently, a second
salvage surgery of his solitary nodule was performed
revealing a yolk sac tumor. He has remained continuously
with no evidence of disease (NED) for 37 months from his
second salvage surgery. However, he developed secondary
acute myeloid leukemia and underwent allogeneic BMT, and
he has been leukemia-free for 24 months.
The third patient presented with a large anterior medi-
astinal mass and 2 right lower lobe pulmonary nodules and
AFP of 36,000 ng/mL. He was treated with 4 courses of eto-
poside, ifosfamide, and cisplatin with AFP nadir 137 ng/mL.
However, AFP rose to 4000 ng/mL several weeks later. He
underwent tumor resection, and pathology revealed a yolk
sac tumor. His AFP brieﬂy declined, but then rapidly rose
4 months later to 1064 ng/mL, and a chest computed
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tandem HDCT and he has remained continuously NED for
50 months.
Eleven of 12 patients received both cycles of HDCT.
Median progression-free survival from the ﬁrst day of HDCT
was 4months (range, 0-50months) andmedian survival was
11 months (range, 5-52 months). Five patients received
maintenance daily oral etoposide. Eight patients received
subsequent therapies (Table 2). Four patients received
subsequent palliative radiation, including 1 patient with
whole brain radiation. Three patients had salvage surgery
including 1 patient with a craniotomy. All 3 patients had
viable tumors at the time of salvage surgery.
Toxicity
Toxicity related to HDCT has been reported previously
[7]. No toxic deaths occurred in these patients. One patient
developed secondary acute myelogenous leukemia 2 years
after HDCT. He had been treated with HDCT as second-line
chemotherapy and also received maintenance daily oral
etoposide. This patient was treated with allogeneic BMT and
is currently alive and disease-free of both leukemia and
PMNSGCT.
DISCUSSION
The principles of management of patients with
PMNSGCTs parallel those of metastatic nonseminomatous
testicular germ cell tumors. However, these patients clearly
have a much worse prognosis, especially in the relapsed
setting. Our results with HDCT and tandem transplantation
for recurrent PMNSGT remain unsatisfactory despite
switching from BMT to PBSCT. Ninety-one percent of our
patients were able to receive a second course of HDCT. There
were no treatment-related deaths. Thus, despite the excel-
lent supportive care, rapid engraftment with PBSCT, and
timely delivery of the second round of HDCT, patients
continued to have inferior results, compared to other forms
of germ cell tumor treated in similar fashion.
Hartmann et al. [4] described a retrospective study of 79
patients with PMNSGCT who had relapsed or progressed on
a cisplatin-based regimen. The long-term DFS for patients
who underwent conventional chemotherapy versus HDCT
with BMT were 11% and 12%, respectively. Twenty-two of 79
patients with PMNSGCT (28%) received HDCT at relapse.
However, the authors did not give a breakdown of howmany
of these patients had subsequent salvage surgery after
chemotherapy that resulted in long-term survival.
Feldman et al. [12] at Memorial Sloan-Kettering Cancer
Center reported their TI-CE regimen for relapsed germ cell
tumors using 2 cycles of preoperative chemotherapy (pacli-
taxel plus ifosfamide) before stem cell collection followed by
triple transplantation with high-dose carboplatin and eto-
poside. They reported DFS in 5 of 21 patients in relapsed
PMNSGCT (24%) with a median DFS of 8.6 months [12].
Our standard of care at Indiana University is to attempt
salvage surgery in operable patients with PMNSGCT at ﬁrst
relapse if the disease is limited to the mediastinum and
technically feasible, similar to our approach to chemo-
refractory metastatic retroperitoneal testicular cancer, if the
disease is conﬁned to the retroperitoneum [13]. Eight ofthese 12 patients had already received salvage surgery before
HDCT.We recently reported our results with surgery alone in
35 patients with relapsed PMNSGCTs with rising serum AFP
(32 patients) or human chorionic gonadotropin (3 patients).
Seven of 35 patients (20%) remained continuously disease-
free with median follow-up of 64 months [14]. Surgical
techniques and outcomes have been described by both the
Memorial Sloan-Kettering Cancer Center and Indiana
University groups [14,15].
In our experience, results with relapsed PMNSGCT with
HDCTand either bonemarrow or peripheral blood transplant
remains unsatisfactory. However, occasional patients have
the potential to achieve CR with some potential for cure. We
continue to recommend salvage surgery rather than salvage
chemotherapy if anatomically feasible and performed with
experienced thoracic surgical oncologists.
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